An Israeli biopharmaceutical company turning injections into once-daily pills. Entera Bio develops oral tablets of hormones like parathyroid hormone (PTH), aiming to treat conditions such as osteoporosis and hypoparathyroidism that normally require daily shots, using its proprietary N-Tab platform that helps fragile peptides survive digestion. Founded in 2009 by Phillip Schwartz and Zeev Bronfeld, it reportedly began as a two-person operation in the storage room of an apartment before growing into a NASDAQ-listed company.
Select a row to see that insider’s individual transactions. † Sum of the holdings confirmed in the 12 months before this insider's last filing. A Form 4 reports a holding per line — held directly, or through a named trust, partnership or foundation, and in each share class separately — never a person’s total. Lines not restated in that time are left out and shown apart: an active filer restates what they still hold, so a line they did not restate is more often an entity since renamed, whose shares a successor line reports too. An amber marker means some were left out.
Net open-market activity over the last 3 years: +166.5K shares. Grants, option exercises and tax withholding are excluded — they are compensation mechanics, not decisions to buy or sell.